AffyImmune Therapeutics to Participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech Conference

NATICK, Mass.--(BUSINESS WIRE)-- AffyImmune Therapeutics, a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, today announced that Matt Britz, President, will participate in a virtual fireside chat at the Evercore ISI 2024 Emerging Biotech Conference on February 29, 2024.

The discussion will be available via a listen-only live webcast accessible at https://wsw.com/webcast/evercore40/affyi/2535793. The webcast will be available for replay at https://affyimmune.com/news/ starting March 4, 2024, and will remain archived following the conference.

About AffyImmune Therapeutics

AffyImmune is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR-T cell therapies to transform the lives of patients with cancer. The Company’s proprietary technology utilizing ICAM1/LFA-1 interaction can potentially address all critical CAR-T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion, while also allowing in vivo tracking of the CAR-T cells. Its lead candidate, AIC100, is a ICAM1-directed CAR-T therapy being developed for patients with advanced thyroid cancer. AffyImmune is developing a focused pipeline of therapeutics targeting ICAM-1 in oncologic indications with high unmet medical need. AffyImmune is based in Natick, MA. For more information, visit www.affyimmune.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220020664/en/